# Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)

> **NCT04877132** · — · APPROVED_FOR_MARKETING · sponsor: **Sanofi**

## Conditions studied

- Sphingomyelin Lipidosis

## Interventions

- **DRUG:** olipudase alfa (GZ402665)

## Key facts

- **NCT ID:** NCT04877132
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877132, "Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04877132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*